Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168369 | 0.92 | VSIR (0.42) | VSIRCD274FOLH1C3AR1 | |
| SCHEMBL21168272 | 0.91 | VSIR (0.43) | VSIRCD274FOLH1 | |
| SCHEMBL21168358 | 0.91 | VSIR (0.43) | VSIRCD274FOLH1C3AR1 | |
| SCHEMBL21168371 | 0.88 | VSIR (0.42) | VSIRCD274FOLH1 | |
| SCHEMBL23351216 | 0.88 | VSIR (0.42) | VSIRCD274FOLH1C3AR1 | |
| SCHEMBL21999114 | 0.88 | VSIR (0.42) | VSIRCD274FOLH1C3AR1 | |
| SCHEMBL21168267 | 0.86 | VSIR (0.46) | VSIRCD274FOLH1C3AR1 | |
| SCHEMBL21168315 | 0.85 | FOLH1 (0.41) | VSIRCD274FOLH1 | |
| SCHEMBL21168316 | 0.85 | FOLH1 (0.47) | VSIRCD274FOLH1 | |
| SCHEMBL21168311 | 0.84 | VSIR (0.42) | VSIRCD274FOLH1C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | CD47, CD63, CD99 | VSIR 2447/4885CD274 20/4885FOLH1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.